Portfolio company
Ikarovec
United Kingdom
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops bicistronic gene therapies to treat chronic ophthalmic diseases, such as age-related macular degeneration, for patients suffering from vision loss.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
PulseSight Therapeutics
This company develops non-viral gene therapies for patients with severe eye diseases including age-related macular degeneration.
Iveric Bio
This biopharmaceutical company develops therapeutic treatments for retinal diseases and provides these medicines to patients with age-related macular degeneration and inherited conditions.
Cirrus Therapeutics
This company develops gene and cell therapies to treat age-related macular degeneration and chronic vision loss for patients with blinding eye diseases.
Beacon Therapeutics
This company develops ophthalmic gene therapies to restore vision for patients with rare and prevalent retinal diseases causing blindness.
EyeBio
This biotechnology company develops ocular therapies to treat retinal diseases such as diabetic macular edema and age-related macular degeneration for patients with vision loss.
Eyexora
This company develops therapeutics and medical devices for ophthalmic diseases to treat patients with vision-threatening conditions.
RhyGaze
This biotechnology company develops optogenetic gene therapies to restore vision for patients with retinal diseases causing blindness.
Atsena
This clinical-stage gene therapy company develops genetic medicines to reverse or prevent blindness for patients with inherited retinal diseases.
